Semaglutide Therapy for Alcohol Reduction - Tulsa

NCT05891587 on ClinicalTrials.gov · last registry update 2025-12-17

Finished 30 July 2025, after enrolling 80 people. Primary outcome, as filed: Change in alcohol drinks per drinking day. semaglutide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Oklahoma State University Center for Health Sciences
Sponsor type: Other
Enrollment: 80
Started: 2023-07-07
Primary completion: 2025-07-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in alcohol drinks per drinking day.

Conditions studied

Alcohol Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.